Donald Smith & Company Has Decreased By $606,702 Its Natuzzi Spa (NTZ) Position; Profile of 4 Analysts Covering Amphastar Pharmaceuticals (AMPH)

May 31, 2017 - By Peter Erickson

Among 5 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Amphastar Pharmaceuticals had 9 analyst reports since August 10, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Tuesday, January 19 report. The firm has “Buy” rating by Needham given on Tuesday, May 10. Zacks downgraded the shares of AMPH in report on Monday, August 10 to “Buy” rating. Raymond James downgraded it to “Outperform” rating and $18 target in Tuesday, March 14 report. The rating was initiated by BMO Capital Markets with “Market Perform” on Wednesday, June 29. Jefferies maintained Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) on Tuesday, August 9 with “Buy” rating. As per Tuesday, August 18, the company rating was upgraded by Zacks. The company was initiated on Friday, February 19 by Wells Fargo. See Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) latest ratings:

14/03/2017 Broker: Raymond James Old Rating: Strong Buy New Rating: Outperform Old Target: $21.00 New Target: $18.00 Downgrade

Donald Smith & Company Inc decreased Natuzzi Spa (NTZ) stake by 7.34% reported in 2016Q4 SEC filing. Donald Smith & Company Inc sold 303,351 shares as Natuzzi Spa (NTZ)’s stock rose 2.36%. The Donald Smith & Company Inc holds 3.83M shares with $8.66 million value, down from 4.13M last quarter. Natuzzi Spa now has $130.38 million valuation. The stock rose 1.23% or $0.03 reaching $2.47. About 4,311 shares traded. Natuzzi, S.p.A (ADR) (NYSE:NTZ) has risen 73.33% since May 31, 2016 and is uptrending. It has outperformed by 56.63% the S&P500.

Donald Smith & Company Inc increased Verso Corp stake by 460,279 shares to 1.54 million valued at $10.97M in 2016Q4. It also upped Kb Home (NYSE:KBH) stake by 2.35M shares and now owns 6.76M shares. American International Group (NYSE:AIG) was raised too.

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has market cap of $784.43 million. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. It has a 89.63 P/E ratio. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients products.

About 45,185 shares traded. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 8.19% since May 31, 2016 and is uptrending. It has underperformed by 8.51% the S&P500.

Investors sentiment decreased to 1.32 in 2016 Q4. Its down 1.85, from 3.17 in 2016Q3. It worsened, as 15 investors sold Amphastar Pharmaceuticals Inc shares while 41 reduced holdings. 25 funds opened positions while 49 raised stakes. 21.78 million shares or 49.43% less from 43.07 million shares in 2016Q3 were reported. Citigroup accumulated 73,203 shares. Proshare Advisors Ltd Limited Liability Company reported 36,921 shares. Parkside State Bank And holds 23 shares or 0% of its portfolio. Moreover, Texas Permanent School Fund has 0.01% invested in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Principal Fincl Group Inc holds 0.01% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) or 280,943 shares. Credit Suisse Ag holds 0% of its portfolio in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 75,655 shares. Blackrock Grp Inc reported 66,021 shares. Bancorp Of America Corp De has invested 0% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Chicago Equity Prns Ltd Liability Company owns 102,420 shares. Royal Bank & Trust Of Canada stated it has 0% of its portfolio in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Ameriprise Fincl Inc has invested 0% of its portfolio in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Bogle Investment Limited Partnership De has invested 0.04% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Qs Investors Ltd Liability owns 81,569 shares. Susquehanna Int Group Llp, a Pennsylvania-based fund reported 93,823 shares. 512,773 were accumulated by Jpmorgan Chase.